Literature DB >> 32504406

Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma.

Reham M Abd El-Baky1, Helal F Hetta2,3, Gopala Koneru4, Marwa Ammar5, Engy A Shafik6, Dina A Mohareb7, Muhammad Abbas El-Masry8, Haidi K Ramadan9, Mohamed Zakaria Abu Rahma9, Michael A Fawzy10, Moustafa Fathy10,11.   

Abstract

Hepatitis C virus (HCV) is considered leading cause of cirrhosis and hepatocellular carcinoma (HCC). We aimed to examine the association of IL-6 and IL-10 single-nucleotide polymorphisms with the progression of chronic HCV (CHC) infection to cirrhosis and HCC. For comparative purposes, four groups were enrolled; chronic HCV group (CHC, n = 22), HCV-related liver cirrhosis group (HCV-LC, n = 22), HCV-related HCC group (HCV-HCC, n = 54), and an apparently healthy control group (controls, n = 48). HCC diagnosis and staging were in concordance to Barcelona Clinic Liver Cancer (BCLC) staging system. IL-6 rs-1474347 and IL-10 rs-1800896 genotyping was performed by allelic (VIC- and FAM-labeled) discrimination method using assay-on-demand TaqMan real-time PCR assays. For IL-6 rs1474347, the AA genotype was more frequent in CHC, HCV-LC, and HCV-HCC compared to controls. Also, the IL-6 rs1474347 AC genotype was favorable for the progression of HCV chronic infection to cirrhosis and HCC. On the other hand, the IL-10 rs1800896 TT genotype was found to be prominent in the HCC group. Additionally, the IL-10 rs180096 TT genotype was favorable for the progression of chronic HCV infection to cirrhosis and HCC. Furthermore, higher levels of AFP were observed in HCC patients with IL-6 rs1474347 AA genotype and HCC patients with IL-10 rs1800896 CC and TT genotypes. Screening for IL-6 rs 1474347 AC genotype and IL-10 rs180096 TT genotype as well as the determination of AFP level showed to be good markers for examining the susceptibility of HCV Egyptian patients to develop cirrhosis and HCC.

Entities:  

Keywords:  HCC; HCV; IL-10; IL-6; Polymorphism

Year:  2020        PMID: 32504406     DOI: 10.1007/s12026-020-09126-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  6 in total

Review 1.  Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries.

Authors:  Khaled Abouelezz; Dipen Khanapara; Gaber El-Saber Batiha; Esraa A Ahmed; Helal F Hetta
Journal:  Cancer Manag Res       Date:  2020-11-27       Impact factor: 3.989

2.  IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis.

Authors:  Minghui Zheng; Weizhen Fang; Menglei Yu; Rui Ding; Hua Zeng; Yan Huang; Yuanyang Mi; Chaohui Duan
Journal:  BMC Endocr Disord       Date:  2021-12-09       Impact factor: 2.763

3.  Vincamine Modulates the Effect of Pantoprazole in Renal Ischemia/Reperfusion Injury by Attenuating MAPK and Apoptosis Signaling Pathways.

Authors:  Michael A Fawzy; Sherif A Maher; Mahmoud A El-Rehany; Nermeen N Welson; Nisreen K A Albezrah; Gaber El-Saber Batiha; Moustafa Fathy
Journal:  Molecules       Date:  2022-02-18       Impact factor: 4.411

4.  Anti-Proliferative and Pro-Apoptotic Activities of Synthesized 3,4,5 Tri-Methoxy Ciprofloxacin Chalcone Hybrid, through p53 Up-Regulation in HepG2 and MCF7 Cell Lines.

Authors:  Marwa A Eisa; Moustafa Fathy; Gamal El-Din A A Abuo-Rahma; Mohamed Abdel-Aziz; Maiiada Hassan Nazmy
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

5.  A New EGFR Inhibitor from Ficus benghalensis Exerted Potential Anti-Inflammatory Activity via Akt/PI3K Pathway Inhibition.

Authors:  Rania Alaaeldin; Heba Ali Hassan; Islam M Abdel-Rahman; Reham H Mohyeldin; Nancy Youssef; Ahmed E Allam; Sayed F Abdelwahab; Qing-Li Zhao; Moustafa Fathy
Journal:  Curr Issues Mol Biol       Date:  2022-07-02       Impact factor: 2.976

6.  In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.

Authors:  Rania Alaaeldin; Muhamad Mustafa; Gamal El-Din A Abuo-Rahma; Moustafa Fathy
Journal:  Fundam Clin Pharmacol       Date:  2021-07-30       Impact factor: 2.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.